Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced its CEO, Dr. Elran Haber, will participate in the 8th Annual Microbiome Movement Drug Development Summit Europe in Barcelona, Spain, from January 30 to February 1, 2024.
The summit gathers leading drug developers and microbiome experts to discuss microbiome functionality, translation, clinical development, biomarker discovery, and manufacturing scale-up. Dr. Haber will join two industry panel discussions: “The Future of Microbiome Therapeutics as Co-therapies: Investment & Development Considerations” on January 30, 2024, at 3:30pm GMT, and “Microbiome Business Pioneers: An Evaluation of Microbiome Industry Verticals & Future Perspectives” on February 1, 2024, at 4:15pm GMT.
Dr. Haber will be available for one-on-one meetings at the conference, and interested parties can contact the investor or public relations team.
Got a Questions?
Find us on Socials or Contact us and we’ll get back to you as soon as possible.